Next Article in Journal
Autoantibodies in SLE: Specificities, Isotypes and Receptors
Next Article in Special Issue
Development of PF-06671008, a Highly Potent Anti-P-cadherin/Anti-CD3 Bispecific DART Molecule with Extended Half-Life for the Treatment of Cancer
Previous Article in Journal / Special Issue
Bispecific CD3/HER2 Targeting FynomAb Induces Redirected T Cell-Mediated Cytolysis with High Potency and Enhanced Tumor Selectivity
Article Menu

Export Article

Open AccessReview
Antibodies 2016, 5(1), 1; doi:10.3390/antib5010001

Taking up Cancer Immunotherapy Challenges: Bispecific Antibodies, the Path Forward?

1,2,3,4,†
,
1,2,3,4
,
1,2,3,4
and
1,2,3,4,†,*
1
Inserm, U1068, CRCM, Marseille F-13009, France
2
Aix-Marseille University, Marseille F-13284, France
3
CNRS, UMR7258, CRCM, Marseille F-13009, France
4
Institut Paoli-Calmettes, Marseille F-13009, France
These authors contributed equally to this work.
*
Author to whom correspondence should be addressed.
Academic Editor: Christian Klein
Received: 12 November 2015 / Revised: 15 December 2015 / Accepted: 18 December 2015 / Published: 26 December 2015
(This article belongs to the Special Issue Advances in Bispecific Antibodies)
View Full-Text   |   Download PDF [1284 KB, uploaded 26 December 2015]   |  

Abstract

As evidenced by the recent approvals of Removab (EU, Trion Pharma) in 2009 and of Blincyto (US, Amgen) in 2014, the high potential of bispecific antibodies in the field of immuno-oncology is eliciting a renewed interest from pharmaceutical companies. Supported by rapid advances in antibody engineering and the development of several technological platforms such as Triomab or bispecific T cell engagers (BiTEs), the “bispecifics” market has increased significantly over the past decade and may occupy a pivotal space in the future. Over 30 bispecific molecules are currently in different stages of clinical trials and more than 70 in preclinical phase. This review focuses on the clinical potential of bispecific antibodies as immune effector cell engagers in the onco-immunotherapy field. We summarize current strategies targeting various immune cells and their clinical interests. Furthermore, perspectives of bispecific antibodies in future clinical developments are addressed. View Full-Text
Keywords: bispecific antibody; cancer immunotherapy; NK cells; T-cells; immune effector cells; immuno-checkpoint bispecific antibody; cancer immunotherapy; NK cells; T-cells; immune effector cells; immuno-checkpoint
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Del Bano, J.; Chames, P.; Baty, D.; Kerfelec, B. Taking up Cancer Immunotherapy Challenges: Bispecific Antibodies, the Path Forward? Antibodies 2016, 5, 1.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Antibodies EISSN 2073-4468 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top